Cargando…

Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort

Gallbladder cancer (GBC) is rare in Western populations and data about treatment and outcomes are scarce. This study aims to analyze survival and identify opportunities for improvement using population-based data from a low-incidence country. GBC patients diagnosed between 2005 and 2016 with GBC wer...

Descripción completa

Detalles Bibliográficos
Autores principales: de Savornin Lohman, Elise, de Bitter, Tessa, Verhoeven, Rob, van der Geest, Lydia, Hagendoorn, Jeroen, Haj Mohammad, Nadia, Daams, Freek, Klümpen, Heinz-Josef, van Gulik, Thomas, Erdmann, Joris, de Boer, Marieke, Hoogwater, Frederik, Koerkamp, Bas Groot, Braat, Andries, Verheij, Joanne, Nagtegaal, Iris, van Laarhoven, Cornelis, van den Boezem, Peter, van der Post, Rachel, de Reuver, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226578/
https://www.ncbi.nlm.nih.gov/pubmed/32283627
http://dx.doi.org/10.3390/cancers12040918
_version_ 1783534321584308224
author de Savornin Lohman, Elise
de Bitter, Tessa
Verhoeven, Rob
van der Geest, Lydia
Hagendoorn, Jeroen
Haj Mohammad, Nadia
Daams, Freek
Klümpen, Heinz-Josef
van Gulik, Thomas
Erdmann, Joris
de Boer, Marieke
Hoogwater, Frederik
Koerkamp, Bas Groot
Braat, Andries
Verheij, Joanne
Nagtegaal, Iris
van Laarhoven, Cornelis
van den Boezem, Peter
van der Post, Rachel
de Reuver, Philip
author_facet de Savornin Lohman, Elise
de Bitter, Tessa
Verhoeven, Rob
van der Geest, Lydia
Hagendoorn, Jeroen
Haj Mohammad, Nadia
Daams, Freek
Klümpen, Heinz-Josef
van Gulik, Thomas
Erdmann, Joris
de Boer, Marieke
Hoogwater, Frederik
Koerkamp, Bas Groot
Braat, Andries
Verheij, Joanne
Nagtegaal, Iris
van Laarhoven, Cornelis
van den Boezem, Peter
van der Post, Rachel
de Reuver, Philip
author_sort de Savornin Lohman, Elise
collection PubMed
description Gallbladder cancer (GBC) is rare in Western populations and data about treatment and outcomes are scarce. This study aims to analyze survival and identify opportunities for improvement using population-based data from a low-incidence country. GBC patients diagnosed between 2005 and 2016 with GBC were identified from the Netherlands Cancer Registry. Patients were grouped according to time period (2005–2009/2010–2016) and disease stage. Trends in treatment and overall survival (OS) were analyzed. In total 1834 patients were included: 661 (36%) patients with resected, 278 (15%) with non-resected non-metastatic, and 895 (49%) with metastatic GBC. Use of radical versus simple cholecystectomy (12% vs. 26%, p < 0.001) in early (pT1b/T2) GBC increased. More patients with metastatic GBC received chemotherapy (11% vs. 29%, p < 0.001). OS improved from 4.8 months (2005–2009) to 6.1 months (2010–2016) (p = 0.012). Median OS increased over time (2005–2009 vs. 2010–2016) in resected (19.4 to 26.8 months, p = 0.038) and metastatic (2.3 vs. 3.4 months, p = 0.001) GBC but not in unresected, non-metastatic GBC. In early GBC, patients with radical cholecystectomy had a median OS of 76.7 compared to 18.4 months for simple cholecystectomy (p < 0.001). Palliative chemotherapy showed superior (p < 0.001) survival in metastatic (7.3 versus 2.1 months) and non-resected non-metastatic (7.7 versus 3.5 months) GBC. In conclusion, survival of GBC remains poor. Radical surgery and palliative chemotherapy appear to improve prognosis but remain under-utilized.
format Online
Article
Text
id pubmed-7226578
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72265782020-05-18 Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort de Savornin Lohman, Elise de Bitter, Tessa Verhoeven, Rob van der Geest, Lydia Hagendoorn, Jeroen Haj Mohammad, Nadia Daams, Freek Klümpen, Heinz-Josef van Gulik, Thomas Erdmann, Joris de Boer, Marieke Hoogwater, Frederik Koerkamp, Bas Groot Braat, Andries Verheij, Joanne Nagtegaal, Iris van Laarhoven, Cornelis van den Boezem, Peter van der Post, Rachel de Reuver, Philip Cancers (Basel) Article Gallbladder cancer (GBC) is rare in Western populations and data about treatment and outcomes are scarce. This study aims to analyze survival and identify opportunities for improvement using population-based data from a low-incidence country. GBC patients diagnosed between 2005 and 2016 with GBC were identified from the Netherlands Cancer Registry. Patients were grouped according to time period (2005–2009/2010–2016) and disease stage. Trends in treatment and overall survival (OS) were analyzed. In total 1834 patients were included: 661 (36%) patients with resected, 278 (15%) with non-resected non-metastatic, and 895 (49%) with metastatic GBC. Use of radical versus simple cholecystectomy (12% vs. 26%, p < 0.001) in early (pT1b/T2) GBC increased. More patients with metastatic GBC received chemotherapy (11% vs. 29%, p < 0.001). OS improved from 4.8 months (2005–2009) to 6.1 months (2010–2016) (p = 0.012). Median OS increased over time (2005–2009 vs. 2010–2016) in resected (19.4 to 26.8 months, p = 0.038) and metastatic (2.3 vs. 3.4 months, p = 0.001) GBC but not in unresected, non-metastatic GBC. In early GBC, patients with radical cholecystectomy had a median OS of 76.7 compared to 18.4 months for simple cholecystectomy (p < 0.001). Palliative chemotherapy showed superior (p < 0.001) survival in metastatic (7.3 versus 2.1 months) and non-resected non-metastatic (7.7 versus 3.5 months) GBC. In conclusion, survival of GBC remains poor. Radical surgery and palliative chemotherapy appear to improve prognosis but remain under-utilized. MDPI 2020-04-09 /pmc/articles/PMC7226578/ /pubmed/32283627 http://dx.doi.org/10.3390/cancers12040918 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
de Savornin Lohman, Elise
de Bitter, Tessa
Verhoeven, Rob
van der Geest, Lydia
Hagendoorn, Jeroen
Haj Mohammad, Nadia
Daams, Freek
Klümpen, Heinz-Josef
van Gulik, Thomas
Erdmann, Joris
de Boer, Marieke
Hoogwater, Frederik
Koerkamp, Bas Groot
Braat, Andries
Verheij, Joanne
Nagtegaal, Iris
van Laarhoven, Cornelis
van den Boezem, Peter
van der Post, Rachel
de Reuver, Philip
Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
title Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
title_full Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
title_fullStr Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
title_full_unstemmed Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
title_short Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
title_sort trends in treatment and survival of gallbladder cancer in the netherlands; identifying gaps and opportunities from a nation-wide cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226578/
https://www.ncbi.nlm.nih.gov/pubmed/32283627
http://dx.doi.org/10.3390/cancers12040918
work_keys_str_mv AT desavorninlohmanelise trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT debittertessa trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT verhoevenrob trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT vandergeestlydia trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT hagendoornjeroen trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT hajmohammadnadia trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT daamsfreek trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT klumpenheinzjosef trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT vangulikthomas trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT erdmannjoris trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT deboermarieke trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT hoogwaterfrederik trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT koerkampbasgroot trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT braatandries trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT verheijjoanne trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT nagtegaaliris trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT vanlaarhovencornelis trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT vandenboezempeter trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT vanderpostrachel trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort
AT dereuverphilip trendsintreatmentandsurvivalofgallbladdercancerinthenetherlandsidentifyinggapsandopportunitiesfromanationwidecohort